These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 12581567)

  • 1. The value of [18F]fluoro-2-deoxy-D-glucose positron emission tomography in the selection of patients with stage IIIA-N2 non-small cell lung cancer for combined modality treatment.
    Hoekstra CJ; Stroobants SG; Hoekstra OS; Vansteenkiste J; Biesma B; Schramel FJ; van Zandwijk N; van Tinteren H; Smit EF
    Lung Cancer; 2003 Feb; 39(2):151-7. PubMed ID: 12581567
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The predictive value of
    Mattoli MV; Massaccesi M; Castelluccia A; Scolozzi V; Mantini G; Calcagni ML
    Radiat Oncol; 2017 Jan; 12(1):4. PubMed ID: 28057034
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PET-FDG scan enhances but does not replace preoperative surgical staging in non-small cell lung carcinoma.
    Poncelet AJ; Lonneux M; Coche E; Weynand B; Noirhomme P;
    Eur J Cardiothorac Surg; 2001 Sep; 20(3):468-74; discussion 474-5. PubMed ID: 11509265
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biological correlates of the maximum 18-fluoro-2-deoxy-glucose uptake on positron emission tomography in non-small cell lung carcinoma after induction chemotherapy.
    Dooms C; Verbeken E; Stroobants S; Vansteenkiste J
    J Thorac Oncol; 2009 Oct; 4(10):1221-5. PubMed ID: 19641474
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of Staging With Positron-emission Tomography (PET) and Comorbidities on Management and Survival of American Veterans With Stage I-III Non-Small Cell Lung Cancer.
    Raghunathan R; Cease K; Troeschel S; Zhao L; Gross M; Chen G; Chopra V; Ramnath N
    Am J Clin Oncol; 2018 May; 41(5):513-518. PubMed ID: 27322696
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumour metabolic activity measured by fluorodeoxyglucose positron emission tomography for radiotherapy planning as a prognostic factor for locally advanced non-small cell lung cancer.
    Masarykova A; Scepanovic D; Povinec P; Bires P; Lederleitner D; Pobijakova M
    Bratisl Lek Listy; 2018; 119(3):133-138. PubMed ID: 29536740
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic stratification of stage IIIA-N2 non-small-cell lung cancer after induction chemotherapy: a model based on the combination of morphometric-pathologic response in mediastinal nodes and primary tumor response on serial 18-fluoro-2-deoxy-glucose positron emission tomography.
    Dooms C; Verbeken E; Stroobants S; Nackaerts K; De Leyn P; Vansteenkiste J
    J Clin Oncol; 2008 Mar; 26(7):1128-34. PubMed ID: 18309948
    [TBL] [Abstract][Full Text] [Related]  

  • 8. False-negative rate after positron emission tomography/computer tomography scan for mediastinal staging in cI stage non-small-cell lung cancer.
    Gómez-Caro A; Boada M; Cabañas M; Sanchez M; Arguis P; Lomeña F; Ramirez J; Molins L
    Eur J Cardiothorac Surg; 2012 Jul; 42(1):93-100; discussion 100. PubMed ID: 22290911
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Detection of extrathoracic metastases by positron emission tomography in lung cancer.
    Weder W; Schmid RA; Bruchhaus H; Hillinger S; von Schulthess GK; Steinert HC
    Ann Thorac Surg; 1998 Sep; 66(3):886-92; discussion 892-3. PubMed ID: 9768946
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Positron emission tomography-computed tomography compared with invasive mediastinal staging in non-small cell lung cancer: results of mediastinal staging in the early lung positron emission tomography trial.
    Darling GE; Maziak DE; Inculet RI; Gulenchyn KY; Driedger AA; Ung YC; Gu CS; Kuruvilla MS; Cline KJ; Julian JA; Evans WK; Levine MN
    J Thorac Oncol; 2011 Aug; 6(8):1367-72. PubMed ID: 21587082
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potential use of FDG-PET scan after induction chemotherapy in surgically staged IIIa-N2 non-small-cell lung cancer: a prospective pilot study. The Leuven Lung Cancer Group.
    Vansteenkiste JF; Stroobants SG; De Leyn PR; Dupont PJ; Verbeken EK
    Ann Oncol; 1998 Nov; 9(11):1193-8. PubMed ID: 9862049
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Value of FDG PET in the management of NSCLC.
    Ukena D; Hellwig D
    Lung Cancer; 2004 Aug; 45 Suppl 2():S75-8. PubMed ID: 15552785
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [18F] 3-deoxy-3'-fluorothymidine positron emission tomography: alternative or diagnostic adjunct to 2-[18f]-fluoro-2-deoxy-D-glucose positron emission tomography in the workup of suspicious central focal lesions?
    Halter G; Buck AK; Schirrmeister H; Wurziger I; Liewald F; Glatting G; Neumaier B; Sunder-Plassmann L; Reske SN; Hetzel M
    J Thorac Cardiovasc Surg; 2004 Apr; 127(4):1093-9. PubMed ID: 15052207
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic relevance of response evaluation using [18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography in patients with locally advanced non-small-cell lung cancer.
    Hoekstra CJ; Stroobants SG; Smit EF; Vansteenkiste J; van Tinteren H; Postmus PE; Golding RP; Biesma B; Schramel FJ; van Zandwijk N; Lammertsma AA; Hoekstra OS
    J Clin Oncol; 2005 Nov; 23(33):8362-70. PubMed ID: 16293866
    [TBL] [Abstract][Full Text] [Related]  

  • 15. When is it best to repeat a 2-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography scan on patients with non-small cell lung cancer who have received neoadjuvant chemoradiotherapy?
    Cerfolio RJ; Bryant AS
    Ann Thorac Surg; 2007 Oct; 84(4):1092-7. PubMed ID: 17888953
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Volume-Based Assessment With 18F-FDG PET/CT Improves Outcome Prediction for Patients With Stage IIIA-N2 Non-Small Cell Lung Cancer.
    Hyun SH; Ahn HK; Ahn MJ; Ahn YC; Kim J; Shim YM; Choi JY
    AJR Am J Roentgenol; 2015 Sep; 205(3):623-8. PubMed ID: 26295651
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interpretation and Prognostic Value of Positron Emission Tomography-Computed Tomography After Induction Chemotherapy With or Without Radiation in IIIA-N2 Non-small Cell Lung Cancer Patients Who Receive Curative Surgery.
    Kim SH; Lee JH; Lee GJ; Jeong S; Kwak YK; Kim HK; Cho DG; Park YH; Yu M; Yoon SC
    Medicine (Baltimore); 2015 Jun; 94(24):e955. PubMed ID: 26091460
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mediastinal lymph node staging with FDG-PET scan in patients with potentially operable non-small cell lung cancer: a prospective analysis of 50 cases. Leuven Lung Cancer Group.
    Vansteenkiste JF; Stroobants SG; De Leyn PR; Dupont PJ; Verschakelen JA; Nackaerts KL; Mortelmans LA
    Chest; 1997 Dec; 112(6):1480-6. PubMed ID: 9404742
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Value of F-18-fluorodeoxyglucose positron emission tomography after induction therapy of locally advanced bronchogenic carcinoma.
    Hellwig D; Graeter TP; Ukena D; Georg T; Kirsch CM; Schäfers HJ
    J Thorac Cardiovasc Surg; 2004 Dec; 128(6):892-9. PubMed ID: 15573074
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Textural features in pre-treatment [F18]-FDG-PET/CT are correlated with risk of local recurrence and disease-specific survival in early stage NSCLC patients receiving primary stereotactic radiation therapy.
    Pyka T; Bundschuh RA; Andratschke N; Mayer B; Specht HM; Papp L; Zsótér N; Essler M
    Radiat Oncol; 2015 Apr; 10():100. PubMed ID: 25900186
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.